Short answer
Bristol Myers Squibb (BMY) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 financial results announced by Bristol Myers Squibb.
Bristol Myers Squibb 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results announced by Bristol Myers Squibb
- Earnings Press Release furnished under Item 2.02 for investor review
- Results and management commentary available at BMS.com
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $11.5B, up 3% reported and 1% Ex-FX, supported by Growth Portfolio revenue growth of 12% to $6.2B
- GAAP EPS $1.31, up 9%; non-GAAP EPS $1.58, down 12%, reflecting higher costs and reduced licensing income
- Gross margin fell to 70.2% from 72.9%, primarily from product mix; GAAP R&D increased 17% to $2.6B
- Legacy Portfolio revenue declined 6% to $5.3B as generic erosion outweighed Eliquis demand growth
- 2026 guidance reaffirmed: revenue ~$46.0B–$47.5B and non-GAAP EPS $6.05–$6.35, trending toward upper ends
Other items in this filing:
- Item 7.01: Regulation FD Disclosure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bristol Myers Squibb 8-K filings
Get the next BMY 8-K as it lands
Follow BMY for push alerts, or ask the research agent what this filing means.